Reconstitution
Formulation-dependent. Oral products may require no reconstitution, while certain injectable pharmaceutical concentrates specify a particular infusion diluent.
BacScience Scientific Research Reference
Alpha-Lipoic Acid Reconstitution & Research Reference
Alpha-lipoic acid (ALA), also called thioctic acid, is a sulfur-containing antioxidant and endogenous metabolic cofactor. This reference examines alpha-lipoic acid chemistry, formulation-specific reconstitution, documented diluent requirements, concentration calculations, stability, storage, sterile-product quality and human clinical research.
Compound Alpha-Lipoic Acid
Synonym Thioctic Acid
Chemical class Dithiolane fatty acid
Formula C8H14O2S2
Molecular weight 206.3 g/mol
Research applications Redox biology, metabolism, neuropathy
Common formulations Oral dosage forms; IV pharmaceutical formulations
Last reviewed September 2026
Alpha-Lipoic Acid Reconstitution & Concentration: Quick Answer
Does alpha-lipoic acid commonly require reconstitution? It depends on the dosage form. Oral ALA products are generally supplied as finished dosage forms. Certain injectable pharmaceutical products are supplied as concentrates or solutions intended for intravenous administration.
Is bacteriostatic water an established universal diluent? No. BAC water should not be treated as a universal ALA diluent. Published pharmaceutical documentation for certain injectable thioctic-acid formulations instead specifies 0.9% sodium chloride.
Is 0.9% sodium chloride universally appropriate for every ALA product? No. The documented saline compatibility applies to specific pharmaceutical formulations. A different ALA product may be ready-to-use or may have different formulation requirements.
What determines concentration? Concentration is determined mathematically by the quantity of ALA divided by the final solution volume.
Important: The mathematical concentration calculation does not establish chemical compatibility, sterility, endotoxin safety, stability, pharmaceutical quality or clinical suitability.
Research Snapshot
The most important considerations for researchers evaluating alpha-lipoic acid material, formulation or concentration.
Diluent
For certain documented injectable thioctic-acid products, 0.9% sodium chloride is specified. This should not be generalized to every ALA material.
Concentration
Concentration is calculated from total ALA mass and final volume. The result is mathematical rather than a formulation validation.
Quality
Identity, assay, impurity profile, material grade, sterility and endotoxin controls must be evaluated separately.
Clinical Evidence
Human research includes oral and intravenous ALA, particularly in diabetic peripheral neuropathy.
Regulatory Status
Regulatory status depends on jurisdiction, formulation, manufacturer and intended route. Research material should not be equated with an approved pharmaceutical preparation.
Diluent warning:
Alpha-lipoic acid is not a simple peptide-like material for which a generic BAC-water recipe can be assumed. The European Pharmacopoeia describes thioctic acid as very slightly soluble in water, while pharmaceutical injectable products may use formulation strategies specifically designed for intravenous administration.
For example, documentation for an injectable thioctic-acid product specifies 0.9% sodium chloride as the solvent and protection from light. Therefore, the formulation documentation for the exact product should control the diluent decision. :contentReference[oaicite:2]{index=2}
What Is Alpha-Lipoic Acid?
Alpha-lipoic acid, commonly abbreviated ALA and also called thioctic acid, is an organosulfur compound containing a 1,2-dithiolane ring and a carboxylic-acid-containing side chain.
PubChem identifies alpha-lipoic acid with molecular formula C8H14O2S2 and molecular weight approximately 206.3 g/mol. The compound is also described as a vitamin-like antioxidant and metabolic cofactor. :contentReference[oaicite:3]{index=3}
How Does Alpha-Lipoic Acid Function Biologically?
Alpha-lipoic acid is associated with mitochondrial energy metabolism because lipoate functions as a cofactor in multienzyme complexes involved in oxidative decarboxylation of alpha-keto acids.
ALA also participates in redox chemistry. Its reduced form, dihydrolipoic acid, can participate in antioxidant and redox processes. These biochemical properties are one reason ALA has been extensively studied in oxidative-stress and metabolic research.
Biochemical antioxidant activity should not automatically be interpreted as evidence of clinical benefit for every condition.
What Is Alpha-Lipoic Acid Being Studied For?
Diabetic Peripheral Neuropathy
This is one of the most extensively investigated clinical applications of ALA. Trials have evaluated both oral and intravenous administration in patients with symptomatic diabetic polyneuropathy.
Oxidative Stress
ALA is investigated as a redox-active compound because of its reversible oxidation-reduction chemistry and relationship to cellular antioxidant systems.
Metabolic Research
Research has examined ALA in glucose metabolism, insulin sensitivity, metabolic dysfunction and related biochemical endpoints.
Neurological Research
ALA has also been investigated in several neurological and neurodegenerative research settings, although evidence varies substantially by indication.
Human Clinical Research
The strongest clinical literature for alpha-lipoic acid concerns symptomatic diabetic distal symmetric polyneuropathy. Importantly, clinical studies have used different routes and formulations.
| Research | Route | Studied ALA | Key finding |
|---|---|---|---|
| ALADIN | IV | 100 / 600 / 1,200 mg daily | 600 and 1,200 mg groups showed greater symptom improvement than placebo over 3 weeks. |
| SYDNEY 2 | Oral | 600 / 1,200 / 1,800 mg daily | Oral ALA improved neuropathic symptoms over 5 weeks, with dose-dependent increases in some adverse effects. |
| ALADIN III | IV → oral | 600 mg IV daily followed by oral therapy | IV treatment produced some short-term findings, while long-term symptom differences were not clearly distinguishable from placebo. |
In the ALADIN trial, 328 patients with symptomatic peripheral neuropathy were randomized to IV ALA at 100, 600 or 1,200 mg/day or placebo for three weeks. The 600 mg group showed significant improvement versus placebo in the primary symptom score. :contentReference[oaicite:4]{index=4}
In SYDNEY 2, 181 patients received oral ALA at 600, 1,200 or 1,800 mg daily for five weeks. All three ALA groups showed improvements in the Total Symptom Score compared with placebo, while nausea, vomiting and vertigo increased with higher doses. :contentReference[oaicite:5]{index=5}
ALADIN III evaluated an initial three-week course of 600 mg IV ALA followed by oral therapy. Although some short-term neurological findings favored ALA, the long-term symptom outcome did not show a clear clinically meaningful difference between treatment groups. :contentReference[oaicite:6]{index=6}
Doses Studied in Clinical Research
Research-dose clarification:
The doses below are examples from published studies and are not recommendations for self-administration or individualized treatment.
| Route | Research Dose | Study Context | Evidence |
|---|---|---|---|
| Oral | 600 mg/day | Diabetic polyneuropathy | Randomized clinical research |
| Oral | 1,200 mg/day | Diabetic polyneuropathy | Randomized clinical research |
| Oral | 1,800 mg/day | Diabetic polyneuropathy | Randomized clinical research |
| IV | 600 mg/day | Diabetic peripheral neuropathy | Randomized clinical research |
These research doses demonstrate why route-specific evidence matters: oral and IV ALA should not be treated as interchangeable formulations.
Routes Studied
Oral
Oral ALA is widely represented in clinical research and is commonly supplied as tablets or capsules.
Intravenous
Pharmaceutical IV formulations of thioctic acid have been studied, particularly for diabetic polyneuropathy. Some products are supplied as concentrates requiring dilution with a specified infusion solution.
Other Research
ALA has also been evaluated in experimental and translational settings using other delivery approaches, but evidence quality varies.
Alpha-Lipoic Acid Reconstitution Research
The diluent depends on the exact ALA formulation.
This is a critical distinction for alpha-lipoic acid.
Certain pharmaceutical injectable thioctic-acid products are supplied as concentrates and have explicit instructions to dilute the product in 0.9% sodium chloride solution.
One product specification states that 600 mg of thioctic acid is diluted in 250 mL of 0.9% sodium chloride and administered as a slow IV infusion. It also specifies protection from light and a limited post-dilution stability period. :contentReference[oaicite:7]{index=7}
Therefore, BAC water should not replace the documented diluent simply because the material is supplied as a powder or concentrate.
Documented for Certain Pharmaceutical Products
- 0.9% sodium chloride
- Formulation-specific dilution volume
- Light protection
- Immediate preparation before administration in certain products
- Formulation-specific post-dilution stability
Not Established as a Universal Rule
- Bacteriostatic water
- Sterile water for every ALA formulation
- Normal saline for every commercial or research product
- A single concentration for all formulations
- A single storage period after reconstitution
Alpha-Lipoic Acid Diluent Considerations
| Diluent | Evidence Position | Interpretation |
|---|---|---|
| 0.9% Sodium Chloride | Documented | Specified in certain pharmaceutical thioctic-acid infusion formulations. |
| Bacteriostatic Water | Not universal | Do not assume compatibility with an ALA powder or injectable product without formulation-specific evidence. |
| Sterile Water | Product dependent | Requires formulation-specific documentation. |
| Dextrose solutions | Product dependent | Do not substitute without compatibility documentation. |
The safest scientific interpretation is therefore not “ALA uses BAC water” but rather: the appropriate diluent is formulation-specific, and certain pharmaceutical IV ALA products document 0.9% sodium chloride as the solvent. :contentReference[oaicite:8]{index=8}
Alpha-Lipoic Acid Concentration Calculator
The mathematical relationship between compound quantity and final solution volume is:
Concentration (mg/mL) = Total ALA (mg) ÷ Final Volume (mL)
For example, a hypothetical solution containing 600 mg of ALA in a final volume of 250 mL has a mathematical concentration of:
600 mg ÷ 250 mL = 2.4 mg/mL
This mathematical result does not by itself establish that 250 mL is appropriate for every ALA product. The example reflects the type of concentration found in documented pharmaceutical infusion instructions, not a universal preparation instruction.
The BacScience Universal BAC Water Calculator can be used for mathematical concentration and volume conversions.
Open Universal BAC Water Calculator
Calculator limitation:
The BacScience calculator performs mathematical conversions. It does not determine whether BAC water, sterile water, saline, dextrose or another diluent is chemically compatible with a particular ALA formulation. It also does not validate sterility, endotoxin, stability, route or clinical suitability.
Vial Quantity & Final Concentration
ALA products can be supplied in different quantities and dosage forms. Researchers should distinguish the labeled amount of active ingredient from the final solution volume.
| Variable | Meaning | Example |
|---|---|---|
| Total ALA | Mass of alpha-lipoic acid present | 600 mg |
| Final volume | Total volume after dilution | 250 mL |
| Mathematical concentration | Total mass divided by final volume | 2.4 mg/mL |
Pharmaceutical labeling should take precedence over generic calculations when preparing a finished medicinal product.
Alpha-Lipoic Acid Stability & Storage Research
Light sensitivity is a particularly important formulation consideration for alpha-lipoic acid.
Pharmaceutical product documentation for injectable thioctic acid specifies that the active substance is photosensitive and that prepared infusion solutions should be protected from light. Some documented products specify stability of approximately six hours when adequately protected from light. :contentReference[oaicite:9]{index=9}
Light
Protect formulations when the applicable product documentation identifies photosensitivity. Light protection should be considered a formulation requirement rather than an optional cosmetic measure.
Time
Post-dilution stability can be substantially shorter than the shelf life of the original pharmaceutical product.
Temperature
Storage conditions should follow the validated product specification. Do not extrapolate stability from another ALA formulation.
Container
Container and light-protection characteristics can affect the stability of a photosensitive formulation.
Important:
“Stable for six hours” is not a universal alpha-lipoic-acid rule. It refers to specific documented pharmaceutical formulations and conditions.
Alpha-Lipoic Acid Solubility
The European Pharmacopoeia describes thioctic acid as a yellow crystalline powder that is very slightly soluble in water, while being very soluble in dimethylformamide and freely soluble in methanol. :contentReference[oaicite:10]{index=10}
This property is another reason a generic “mix with BAC water” approach should not be presented as a scientifically established ALA reconstitution protocol.
Do not infer injectability from solubility.
A substance dissolving in a liquid does not establish that the resulting solution is sterile, pyrogen-free, chemically stable or appropriate for parenteral administration.
Sterility & Endotoxin Considerations
Sterility, endotoxin control and chemical purity are separate quality attributes.
Sterility
A sterile injectable preparation requires appropriate sterile manufacturing or compounding controls.
Endotoxin
Low chemical impurity levels do not automatically demonstrate acceptable bacterial endotoxin levels.
Container Closure
Packaging and closure systems must maintain product quality throughout the validated storage period.
Preparation
Reconstitution or dilution for sterile use must follow applicable pharmaceutical or sterile-compounding requirements.
Light Protection
Photosensitive injectable ALA formulations may require light-protective handling.
Beyond-Use Dating
Beyond-use dating should be based on applicable formulation and stability data rather than an arbitrary period.
Alpha-Lipoic Acid Quality & Purity Considerations
A certificate of analysis should be interpreted as one part of a complete quality assessment.
Identity
Confirm that the material is actually alpha-lipoic acid/thioctic acid and identify the stereochemical form where relevant.
Assay
Evaluate the reported amount of active compound and the analytical method used to establish it.
Impurity Profile
Review specified and unspecified impurities using an appropriate validated analytical method.
Material Grade
Research-grade, dietary-grade and pharmaceutical-grade materials should not be treated as interchangeable.
Sterility
Sterility claims require appropriate process and testing support when the material is intended for sterile use.
Endotoxin
Injectable applications require appropriate endotoxin controls independent of chemical assay.
Regulatory Status
Alpha-lipoic acid has different regulatory classifications depending on jurisdiction and dosage form. It is marketed as a dietary supplement in some jurisdictions and is used as an active pharmaceutical ingredient in medicinal products in others.
The existence of a pharmaceutical IV thioctic-acid product does not mean that every alpha-lipoic-acid powder or supplement is suitable for injection.
Researchers should distinguish between:
- dietary-supplement material;
- research material;
- pharmaceutical-grade active ingredient;
- finished medicinal products; and
- compounded sterile preparations.
Alpha-Lipoic Acid Safety Findings
Clinical safety depends on dose, route, formulation, treatment duration and patient characteristics.
- Oral clinical studies have reported gastrointestinal and neurological adverse effects, particularly at higher doses.
- The SYDNEY 2 trial reported dose-dependent increases in nausea, vomiting and vertigo with higher oral ALA doses. :contentReference[oaicite:11]{index=11}
- IV studies have used pharmaceutical formulations under controlled clinical conditions and should not be extrapolated to unvalidated research preparations.
- Severe overdose has been associated with serious toxicity in case reports and pharmaceutical warnings.
- Individuals using glucose-lowering therapies may require particular clinical consideration because ALA has been studied in metabolic settings.
Research Limitations
- ALA research uses different formulations and routes.
- Results from oral ALA cannot automatically establish the efficacy or safety of an injectable formulation.
- Older IV studies used specific pharmaceutical preparations and should not be treated as validation for arbitrary ALA powders.
- Clinical outcomes differ according to indication and endpoint.
- A mathematical concentration calculation does not validate a formulation.
- Stability information should be specific to the formulation, concentration, container and storage conditions.
Alpha-Lipoic Acid FAQ
What is alpha-lipoic acid?
Alpha-lipoic acid is a sulfur-containing metabolic cofactor and vitamin-like antioxidant also known as thioctic acid.
What is the molecular weight of alpha-lipoic acid?
Alpha-lipoic acid has a molecular weight of approximately 206.3 g/mol and molecular formula C8H14O2S2.
Does alpha-lipoic acid need reconstitution?
It depends on the formulation. Oral products generally do not require reconstitution. Some injectable pharmaceutical products are supplied as concentrates requiring dilution.
Can alpha-lipoic acid be reconstituted with BAC water?
BAC water should not be assumed to be an appropriate universal diluent. Certain pharmaceutical injectable ALA products specifically document 0.9% sodium chloride as the solvent.
What diluent is documented for some injectable alpha-lipoic acid products?
Certain pharmaceutical thioctic-acid products specify 0.9% sodium chloride solution for dilution before IV infusion.
Why is alpha-lipoic acid protected from light?
Pharmaceutical documentation identifies thioctic acid as photosensitive and specifies light protection for certain injectable infusion solutions.
How do you calculate alpha-lipoic acid concentration?
Mathematical concentration in mg/mL equals total ALA mass in mg divided by the final solution volume in mL.
Does the BacScience calculator determine the correct ALA diluent?
No. It performs mathematical concentration and volume calculations. It does not establish chemical compatibility, sterility, stability, endotoxin safety or clinical appropriateness.
What has alpha-lipoic acid been studied for?
ALA has been extensively studied in diabetic peripheral neuropathy and has also been investigated in oxidative stress, metabolic and neurological research.
Has intravenous alpha-lipoic acid been studied clinically?
Yes. Randomized trials have studied IV ALA, particularly in diabetic peripheral neuropathy.
Is oral alpha-lipoic acid equivalent to IV alpha-lipoic acid?
No. The route affects formulation, pharmacokinetics, administration requirements and clinical evidence.
Is alpha-lipoic acid water soluble?
The European Pharmacopoeia describes thioctic acid as very slightly soluble in water, which is relevant when evaluating formulation and reconstitution.
Calculate ALA Concentration Mathematically
Use the BacScience Universal BAC Water Calculator for mathematical concentration and volume conversions. Always verify the exact ALA formulation, documented diluent, storage conditions and intended route independently.
Open BAC Water CalculatorScientific References
- PubChem. Alpha-Lipoic Acid, CID 864. Molecular identity, molecular formula and molecular weight. PubChem
- European Pharmacopoeia. Thioctic Acid monograph. Chemical identity, solubility, purity and storage considerations. Reference
- Ziegler D, et al. ALADIN Study. Intravenous alpha-lipoic acid in symptomatic diabetic peripheral neuropathy. PubMed
- Ziegler D, et al. SYDNEY 2. Oral alpha-lipoic acid in symptomatic diabetic polyneuropathy. PubMed
- Ziegler D, et al. ALADIN III. Sequential IV and oral alpha-lipoic acid treatment in diabetic polyneuropathy. PubMed
- Insulipon pharmaceutical product documentation. Injectable thioctic acid formulation, 0.9% sodium chloride dilution and light protection. Product documentation
- Thiogamma Turbo-Set product information. Intravenous thioctic acid administration and light protection. Product information
Last Reviewed
September 11, 2026
This page should be reviewed periodically as new clinical trials, pharmaceutical product documentation, regulatory information and formulation-stability evidence become available.
Research information only. This page is provided for scientific and educational reference. It is not medical advice, prescribing guidance or a substitute for validated pharmaceutical formulation documentation. Alpha-lipoic acid products differ in chemical form, grade, formulation, route and quality controls. Mathematical examples on this page should not be interpreted as instructions for human administration. Injectable preparation should only be performed according to the applicable pharmaceutical product documentation and qualified sterile-compounding requirements.